We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00692718
Recruitment Status : Unknown
Verified June 2008 by Osaka General Medical Center.
Recruitment status was:  Not yet recruiting
First Posted : June 6, 2008
Last Update Posted : June 19, 2008
Information provided by:

Study Description
Brief Summary:
Our study is to investigate the effect of N-3 Fatty Acids for the prevention of atrial fibrillation in patients with acute heart failure or acute myocardial infarction

Condition or disease Intervention/treatment Phase
Acute Heart Failure Acute Myocardial Infarction Drug: Epadel, Eicosapentaenoic acid Phase 4

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure
Study Start Date : July 2008
Estimated Primary Completion Date : June 2010

Arms and Interventions

Intervention Details:
    Drug: Epadel, Eicosapentaenoic acid
    Epadel 900mg, 2 times a day, during hospitalization

Outcome Measures

Primary Outcome Measures :
  1. detection of atrial fibrillation on ECG monitoring [ Time Frame: anytime during hospitalization ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • sinus rhythm patients with acute heart failure or acute myocardial infarction

Exclusion Criteria:

  • pregnancy,allergy to epadel
More Information

Responsible Party: Masaharu Masuda, Osaka Geneeal Medical Cener
ClinicalTrials.gov Identifier: NCT00692718     History of Changes
Other Study ID Numbers: OFAHeft
First Posted: June 6, 2008    Key Record Dates
Last Update Posted: June 19, 2008
Last Verified: June 2008

Additional relevant MeSH terms:
Heart Failure
Atrial Fibrillation
Myocardial Infarction
Heart Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Pathologic Processes
Myocardial Ischemia
Vascular Diseases
Eicosapentaenoic acid ethyl ester
Platelet Aggregation Inhibitors